KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Gross Margin (2016 - 2026)

West Pharmaceutical Services has reported Gross Margin over the past 18 years, most recently at 35.08% for Q1 2026.

  • Quarterly Gross Margin rose 186.0% to 35.08% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 36.28% through Mar 2026, up 174.0% year-over-year, with the annual reading at 35.91% for FY2025, 140.0% up from the prior year.
  • Gross Margin was 35.08% for Q1 2026 at West Pharmaceutical Services, down from 37.75% in the prior quarter.
  • Over five years, Gross Margin peaked at 41.68% in Q2 2022 and troughed at 32.76% in Q2 2024.
  • The 5-year median for Gross Margin is 36.98% (2022), against an average of 36.85%.
  • Biggest five-year swings in Gross Margin: tumbled -590bps in 2024 and later surged 297bps in 2025.
  • Tracing WST's Gross Margin over 5 years: stood at 36.98% in 2022, then grew by 3bps to 38.01% in 2023, then decreased by -4bps to 36.54% in 2024, then increased by 3bps to 37.75% in 2025, then dropped by -7bps to 35.08% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods came in at 35.08%, 37.75%, and 36.58% for Q1 2026, Q4 2025, and Q3 2025 respectively.